Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...
Merck's survival win and Bristol Myers Squibb's second failure further consolidate Keytruda's position as the leading immunotherapy in adjuvant kidney cancer. (Merck and Bristol Myers Squibb) () Merck ...
Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results